Menu

EPA Stalls Release of Carcinogen Report

An investigation by Politico finds the agency has been sitting on an assessment of formaldehyde’s cancer risks for a year and a half.

Jul 9, 2018
Sukanya Charuchandra

ABOVE: The Environmental Protection Agency building in Washington, D.C.
ISTOCK, YINYANG

The Environmental Protection Agency is delaying the release of a draft assessment on formaldehyde that finds the chemical causes nasal and oral cancer and leukemia, according to Politico

The report has been ready since before President Donald Trump’s entry into the White House, yet it hasn’t been forwarded to the National Academies of Sciences for review nor been made public, reports Politico.

Politico’s investigation suggests that Environmental Protection Agency (EPA) officials have been suppressing the report to cater to the chemical industry. “At every corner, you see the agency trying to either minimize the role of science or manipulate the role of science or just ignore the work of scientists in doing the critical work to ensure that human health and the environment is protected,” Jennifer McPartland, a senior scientist with the Environmental Defense Fund, tells Politico. 

EPA denies the accusations. 

According to Vox, Democratic senators in a May letter to former EPA chief Scott Pruit say, “We have also learned that, at the same time as EPA political appointees’ requests were delaying the formaldehyde assessment’s movement through the agency review process, the American Chemistry Council (ACC) as well as interested corporation such as ExxonMobil have been pressuring EPA not to release the assessment for public comment as drafted.”

June 2019

Living with Bacteria

Can pathogens be converted to commensals?

Marketplace

Sponsored Product Updates

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows. Kit developed as part of licensing and supply agreement with Cygnus Technologies
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT’s new CRISPR Cas12a (Cpf1) Ultra enzyme can target new sites within the genome and with greater efficiency
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen GmbH is excited to announce the release of the NanoPhotometer® N120, an absorbance based UV/VIS Multi Channel Spectrophotometer.
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
To continue to provide new products and services to further advance medical research around the world, today, StemExpress announced the release of their Frozen Leukopak®.